Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering ...

Amylyx Pharmaceuticals prices public offering of common stock at $3.50 per share, aiming to raise $60M for commercialization and pipeline programs.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...

Amylyx Pharmaceuticals, Inc. (AMLX), a Massachusetts-based biopharmaceutical company, Friday announced the pricing of an underwritten ...

Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. Amylyx intends to ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a ...

For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.

The health and wellness world never stands still. Even as interest in well-being reaches all-time highs, there are fresh trends on the horizon, and TruLife Distribution founder and CEO Brian Gould ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company ...